All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

GSK's Exdensur (depemokimab) wins Japan approval for severe asthma and chronic rhinosinusitis with nasal polyps
Antibody, respiratory disease, monoclonal antibody, severe asthma, chronic rhinosinusitis, IL-5 pathway - Read more

Ark Biopharmaceutical's Azstarys (serdexmethylphenidate/dexmethylphenidate) wins China approval for attention deficit hyperactivity disorder treatment
Small molecule, neurological, ADHD, methylphenidate, pediatric population - Read more

Zai Lab's AUGTYRO (repotrectinib) wins China approval for neurotrophic tyrosine receptor kinase-positive solid tumors
Small molecule, cancer, tyrosine kinase inhibitor, NTRK fusion, solid tumors - Read more

THE GOOD
Business Development & Partnerships

Gilead, OncoNano Medicine partner on drug delivery cancer platform, $300M total deal value
Research collaboration, oncology, drug delivery, milestone payments - Read more

Eli Lilly, Nimbus Therapeutics partner on preclinical oral obesity drug, $55M upfront, $1.3B milestones
Research collaboration, obesity, small molecule, AI/ML, milestone payments - Read more

Roche, Structure Therapeutics license obesity pill CT-996 patents for $100M upfront, low-single-digit royalties
Licensing deal, small molecule, obesity, royalties, patent agreement - Read more

Boehringer Ingelheim, Variant Bio partner on AI-powered kidney disease target discovery, $120M+ milestones
Research collaboration, kidney disease, AI/ML, drug discovery, milestone payments - Read more

Pfizer, Cartography Biosciences partner on tumor-selective antigen discovery, $65M upfront, $850M total potential
Research collaboration, oncology, drug discovery, milestone payments - Read more

Ikarovec, VectorBuilder partner on eye gene therapy for office delivery, potential $1B deal value
Research collaboration, gene therapy, ophthalmology, AI/ML, milestone payments - Read more

Cyclerion Therapeutics, Medsteer expand collaboration for CYC-126 treatment-resistant depression therapy development
Research collaboration, neurological, digital health, R&D - Read more

AstraZeneca, BostonGene collaborate on AI-powered platform for oncology trials, financial terms undisclosed
Research collaboration, oncology, AI/ML, drug discovery - Read more

AriBio, Fosun Pharma, Newcopharma partner for Alzheimer's treatment AR1001 in ASEAN, 630B KRW ($435.5M) deal
Licensing deal, neurological, commercialization, milestone payments - Read more

Lupin, Gan & Lee Pharmaceuticals partner on exclusive license for bi-weekly GLP-1RA in India
Licensing deal, diabetes, bi-weekly injection, commercialization - Read more

PRESENTED BY SCIENCE 2 SALES
Cold calling in the life sciences - free webinar!

By popular demand, we’re running two webinars on cold calling in the life sciences - our first one was a hit, and there’s one more next week!

We’ll be covering:
• Why cold calling is so powerful right now (hint: points at all the AI everywhere)
• What is (and isn't) cold calling
• When it's worth it (sometimes it's not!)
• Mindset, strategies, and the technical bits behind doing cold calling

And probably a bunch more things - also a special guest 👀

Email [email protected] to get your invite

✅ More Good News ✅

THE GOOD
Clinical Trials

Arrowhead Pharma's ARO-INHBE doubles tirzepatide weight loss in type 2 diabetes patients in Ph1/Ph2a trial
RNAi therapeutics, metabolic, obesity, type 2 diabetes, combination therapy, Activin E pathway - Read more

Alumis' TYK2 inhibitor envudeucitinib hits Ph3 endpoints for moderate to severe plaque psoriasis treatment
Small molecule, autoimmune, TYK2 inhibitor, psoriasis, plaque psoriasis - Read more

Bright Minds Biosciences' BMB-101 shows positive Ph2 results for drug-resistant absence seizures and developmental epilepsies
Small molecule, neurological, serotonin receptor agonist, epilepsy, drug-resistant seizures, 5-HT2C receptor - Read more

AstraZeneca's subcutaneous Saphnelo hits Ph3 goal in systemic lupus erythematosus with 56% response rate
Antibody, autoimmune, monoclonal antibody, systemic lupus erythematosus, type 1 interferon receptor, subcutaneous - Read more

Jazz Pharmaceuticals' Ziihera shows superior progression-free survival versus Herceptin in Ph3 gastroesophageal adenocarcinoma trial
Antibody, cancer, HER2-targeted therapy, gastroesophageal adenocarcinoma, combination therapy - Read more

Johnson & Johnson's nipocalimab (FcRn blocker) meets primary endpoint in Ph2 systemic lupus erythematosus study
Antibody, autoimmune, monoclonal antibody, systemic lupus erythematosus, FcRn blocker, steroid sparing - Read more

HUTCHMED's Sovleplenib (Syk inhibitor) meets Ph3 primary endpoint for warm antibody autoimmune hemolytic anemia in China
Small molecule, autoimmune, Syk inhibitor, warm antibody autoimmune hemolytic anemia, hemoglobin response - Read more

Gilgamesh Pharma's blixeprodil (GM-1020) shows positive Ph2a results targeting NMDA receptors for major depressive disorder
Small molecule, neurological, NMDA receptor antagonist, major depressive disorder, oral administration - Read more

THE GOOD
Fundraises

Chromatin Bioscience, Mediphage Bioceuticals, Entos Pharmaceuticals receive UKRI/NRC IRAP funding, genetic medicines collaboration
Gene therapy, rare disease, genetic medicines, platform technology - Read more

Mediar Therapeutics raises $76M Series B for clinical trials of fibrosis drugs
Fibrosis, clinical-stage, small molecule - Read more [Paywall]

THE GOOD
Mergers & Acquisitons

Amgen to acquire Dark Blue Therapeutics for up to $840M to expand protein-degrading cancer pipeline
Protein degrader, oncology, strategic, major transaction - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development & Partnerships

Instil Bio, ImmuneOnco Biopharmaceuticals end partnership, returns two cancer drugs from $50M deal
Licensing deal, oncology, bispecific antibody, milestone payments - Read more

THE BAD
Regulatory

FDA rejects Sanofi's tolebrutinib (BTK inhibitor) for non-relapsing secondary progressive multiple sclerosis citing liver injury risks
Small molecule, neurological, BTK inhibitor, multiple sclerosis, liver toxicity - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here